Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy, but the large number of HSCs required limits its widespread use. Host conditioning and donor cell composition are known to affect HSCT outcomes. However, the specific role that the posttransplantation signaling environment plays in donor HSC fate is poorly understood. To mimic clinical HSCT, we injected human umbilical cord blood (UCB) cells at different doses and compositions into immunodeficient NOD/SCID/IL-2Rgc-null (NSG) mice. Surprisingly, higher UCB cell doses inversely correlated with stem and progenitor cell engraftment. This observation was attributable to increased donor cell-derived inflammatory signals. Donor T cell-derived tumor necrosis factor- (TNF) was specifically found to directly impair the survival and division of transplanted HSCs and progenitor cells. Neutralizing donor T cell-derived TNF in vivo increased short-term stem and progenitor cell engraftment, accelerated hematopoietic recovery, and altered donor immune cell compositions. This direct effect of TNF on transplanted cells could be decoupled from the indirect effect of alleviating graft-versus-host disease (GVHD) by interleukin-6 (IL-6) blockade. Our study demonstrates that donor immune cell-derived inflammatory signals directly influence HSC fate, and provides new clinically relevant strategies to improve engraftment efficiency during HSCT.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for patients with hematologic diseases. However, 70% of patients do not have a matched related donor (1) . Finding matched unrelated donors is clinically beneficial but has proven challenging especially for the minority of patients (2) . Umbilical cord blood (UCB) provides a source of transplantable HSCs with several advantages (3) . However, the limited number of hematopoietic stem and progenitor cells (HSPCs) available in single UCB units is associated with delayed hematopoietic recovery and a higher risk of graft failure, which are major complications that contribute to transplant-related mortality (TRM) in adult patients during the early posttransplantation phase (4) . Potential strategies to improve engraftment include transplantation of double UCB units (5, 6) , ex vivo expansion of HSPCs (7) (8) (9) (10) (11) , and increasing HSPC homing (12, 13) . Despite encouraging results reported in early-phase clinical studies (9, 10, (12) (13) (14) (15) , the requirement for high cell numbers to overcome apparent low stem cell engraftment efficiencies remains poorly understood.
Accumulating evidence demonstrates that transplantation of HSCs alone is not sufficient to ensure robust engraftment and patient survival (16, 17) . Coinfusion of lineage-committed progenitors and mature hematopoietic and immune cells has been associated with accelerated hematopoietic reconstitution (10) , prevention of opportunistic infections (18) , and exerting graft-versus-leukemia effects (19) . In addition, pretransplant conditioning appears to induce host tissue damage and inflammation, leading to donor immune cell activation and secretion of inflammatory factors and graft-versus-host disease (GVHD) (20) . One promising therapeutic strategy to attenuate acute GVHD focuses on characterizing the secreted factor dynamics during the early posttransplantation phase and using specific factor-targeting biologics (21, 22) . We previously demonstrated that cell feedback networks regulate HSC fate during homeostasis or in vitro culture (8, (23) (24) (25) . Here, we report that upon transplantation, donor immune cell-mediated inflammatory signals feedback to donor stem and progenitor cells and affect short-term HSC engraftment and hematopoietic recovery. Furthermore, specifically blocking these inflammatory signals using a monoclonal antibody enhances bone marrow (BM) reconstitution levels and diversity and accelerates peripheral hematopoietic recovery rates.
RESULTS

UCB cell dose and composition affect short-term progenitor cell engraftment
Purified human CD34 + cells have typically been used to model HSCT in preclinical mouse models. To better understand how cotransplantation of CD34 + and differentiated/immune cells affects donor HSPC engraftment, we transplanted single, unfractionated human UCB units into sublethally irradiated NOD/SCID/IL-2Rgc-null (NSG) mice (Fig. 1A ). First, we tested UCB doses of 0.5 × 10 6 , 1 × 10 6 , or 5 × 10 6 cells to examine cell dose-dependent effects on hematopoietic reconstitution. Infusion of 2.5 × 10 4 CD34 + cells (>98% purity) isolated from the same UCB unit served as a control (tables S1 and S2) (26) . This experiment was limited to 28 days because, after 17 days, mice transplanted with 5 × 10 6 UCB cells experienced significant weight loss (P = 0.034) and other GVHD-related symptoms according to the standard GVHD scoring metric ( fig. S1 ) (27) . We observed human (CD45 + HLA-ABC + ) cell engraftment in the BM by day 28 in all transplantation conditions ( fig. S2A ). Fold changes in the number of CD34 + and CD34 + CD45RA − CD90 + HSCenriched cells (hereafter referred to as HSC-e) in relation to the number transplanted decreased with increasing UCB doses (Fig. 1B) . These changes correlated with greater proportions of donor-derived mature immune cells [T and natural killer (NK)] and lower proportions of progenitors [precursor NKT (preNKT), progenitor B (proB), and megakaryocytic progenitor (MegaP)] and mature cells of other lineages [B, megakaryocyte (Mega), granulocyte (Gran), and monocyte (Mono)] present in the BM (Fig. 1C and fig. S2 ). The inverse relationship between the input UCB cell dose and the engraftment level and the predominant presence of donor immune cells at higher UCB doses imply that both the UCB dose and the coinfused immune cells could affect the short-term engraftment level of phenotypically enriched stem and progenitor cells. These observations motivated us to investigate the effect of immune cells on donor HSPC fate after transplantation.
Secreted donor-derived inflammatory factors affect in vitro HSC-e cell proliferation and differentiation
We hypothesized that inflammatory factor secretion from donor immune cells, upon exposure to irradiation-induced damage in host tissue and alloantigens, negatively affects transplanted HSPC function. To test this, we first measured human factor concentrations in the sera of UCB-infused mice. An array of human inflammatory factors was elevated within 2 weeks of UCB (5 × 10 6 ) infusion ( Fig. 2A and fig.  S3 ). Notably, these factors were not detected when purified CD34 + cells were transplanted alone. Next, using our previously published bioinformatics strategy (25) , we found that seven of the elevated inflammatory factors, whose levels were 10 times the assay detection limit (arbitrarily set threshold; >32 pg/ml), have cognate receptors expressed by human HSCs at the transcriptional level ( Fig. 2A and table S5 ). Among these seven factors, interleukin-6 (IL-6), granulocyte-monocyte colony-stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), and tumor necrosis factor- (TNF) were examined in our previous studies using an enriched HSC population (Lin (25, 26) . It was found that IL-6 (26) and GM-CSF (25) stimulate the proliferation and differentiation of these cells, that VEGF has no direct effect (25) , and that TNF inhibits HSC proliferation (25) . Therefore, we sought to examine TNF plus the three remaining factorsinterferon-inducible cytokine (IP-10), interferon- (IFN), and monocyte chemotactic protein 1 (MCP-1)-at concentrations relevant to those detected in the mouse serum using the same assay described previously ( Fig. 2B) (25) . No effects were detected for IP-10 and MCP-1 compared to the "3F" condition containing stem cell factor (SCF), thrombopoietin (TPO), and FMS-like tyrosine kinase 3 ligand (Flt3L) (hereafter referred to as control) (Fig. 2C and fig. S4 ). In the presence of IFN (10 ng/ml), the number of HSC-e decreased, whereas the number of differentiated cells increased, suggesting that IFN acts in a differentiation-inducing manner. The presence of TNF resulted in a significant reduction of both HSC-e and progenitor cell compartments at 1 ng/ml (P < 0.01). It is worth noting that the differentiated cell population was only affected by TNF at concentrations greater than 1 ng/ml, as we previously showed (25) . These data indicate a dose-dependent effect of TNF on specific cell populations at different developmental stages.
TNF inhibits HSPC proliferation via TNF receptor 1
To directly study the effects of TNF on HSPCs, purified CD34 + cells were cultured with TNF (1 ng/ml) for a 7-day period. We observed that both the percentage and fold expansion of CD34 + and CD34 + CD45RA − CD90 + HSC-e cells were significantly impaired in the presence of TNF (Fig. 3, A and B, and fig. S5 ). We next measured TNF receptor 1 (TNFR1) and TNFR2 expression levels because these two receptors bind to TNF. Most (>90%) of the HSPCs expressed TNFR1, whereas only a small percentage (<10%) expressed TNFR2 ( fig. S6) (purple) were individually tested at three different doses (ng/ml) indicated by different shades for each factor. Two-tailed Kruskal-Wallis test and Mann-Whitney U test with Bonferroni correction (P adj = 0.983) were performed to compare each test condition to the control group. Data are from four or five independent experiments (n = 3 within each experiment). Two to five pooled UCB units were used per experiment. *P < 0.05; **P < 0.01; ***P < 0.001; and not significant (n.s.), P ≥ 0.05.
the function of these two receptors, we used specific TNFR1-and TNFR2-blocking antibodies. Consistent with the receptor expression levels, blocking TNFR1 effectively abolished TNF-induced reduction in CD34 + and HSC-e numbers, whereas blocking TNFR2 did not (Fig. 3 , C and D). No additive effect was observed when both antibodies were introduced. In parallel, we tested the clinically available TNF -neutralizing agent, etanercept (Enbrel, Amgen) (28), and as expected, its addition blocked TNF-mediated effects. Collectively, these results, together with those from enriched HSC cultures (Fig. 2C) , implicate TNF as a potent inhibitory factor for the stem and progenitor cell compartment, consistent with previous studies (29) (30) (31) (32) .
TNF affects HSC survival and cell cycle progression and activates the nuclear factor B pathway For a deeper mechanistic understanding of TNF signaling effects on HSPCs, we investigated apoptosis in our CD34 + cell cultures. In the presence of TNF, the annexin-V (Fig. 4A) . This was corroborated with a greater proportion of HSCs in G 0 (Ki67 − 2n DNA content) after 2 days of culture with TNF ( Fig. 4B and fig. S8 ). Moreover, to interrogate the downstream responses of HSCs upon TNF stimulation, seven intracellular signaling targets were measured using single-cell mass cytometry (table S7) + HSCs, TNF uniquely activated the nuclear factor B (NFB) pathway as indicated by increased levels of phosphorylated p65 and decreased levels of IB (inhibitor of NFB), whereas the control condition activated different pathways including extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, S6, signal transducer and activator of transcription 3 (STAT3), and STAT5 (Fig. 3, C and  D, and fig. S9 ). However, when a pharmacological inhibitor of the NFB pathway-Bay 11-7085 (10 M)-was present, HSCs appeared stationary, and no cell divisions were observed (movie S3). This suggests a positive role for the NFB pathway in counteracting TNF signals.
Together, these data demonstrate that TNF leads directly to cell death and prolongs cell division time in human HSCs.
Donor-derived memory T cells secrete TNF
Given that donor-derived TNF is elevated when HSPC engraftment is compromised, and that TNF directly impairs the survival and division of phenotypically enriched HSCs in vitro, we next interrogated the direct effect of TNF on donor HSPC engraftment and reconstitution in vivo. These experiments were carried out for 17 days at a maximum dose of 3 × 10 6 UCB cells, conditions where no significant weight loss and GVHD symptoms were observed ( fig. S10 ).
To determine which donor-derived immune cell population(s) is(are) the source of TNF, we used single-cell mass cytometry to measure the expression of five intracellular proteins (TNF, IFN, IL-6, perforin, and granzyme B) and 23 surface antigens ( (Fig. 5A ). Significant levels of TNF were detected when cells harvested from the recipient BM were subjected to a 4-hour pharmacological stimulation with phorbol 12-myristate 13-acetate and ionomycin ( fig. S11B ). The TNF-producing population was clustered in a subset of memory CD4 + or CD8 + T cells that had an activated (CD38 + HLA-DR + ) phenotype (Fig. 5B) . A significant IFN response was also obtained in the Shown are means ± SD from at least two independent experiments. *P < 0.05; **P < 0.01; and ***P < 0.001.
same cell subsets; however, we did not detect any IL-6 signal ( fig.  S11C) . Note that the level of granzyme B expressed in the CD34 + cell population was 3 ± 1.2-fold higher in transplantations with unpurified UCB than with enriched CD34 + cells, suggesting that HSPCs experienced more stress (35) when mature immune cells were cotransplanted ( fig. S11D) . Together, this system-wide analysis of donor-derived cell subsets present in the recipient BM during the early posttransplantation phase reveals that the activated subsets of memory T cells are the major source of TNF.
Etanercept enhances short-term HSPC engraftment and accelerates hematopoietic recovery
Capitalizing on the availability of clinically approved TNF-neutralizing agents, we next investigated whether TNF inhibition by etanercept would improve short-term HSPC engraftment numbers and hematopoietic recovery, a clinically important phase for HSCT (36) . Infusions of the equivalent number of CD34 + cells were included as controls ( cells of other lineages (Gran, Mono, and EryB), compared to the UCB control groups (Fig. 6C and fig. S15 ). Only in the etanercept treatment group were significant percentages of human myeloid (CD33 + ) and megakaryocytic (CD41 + ) cells detected by day 17 in the peripheral blood (PB) (fig. S16 ). The improved reconstitution number and diversity in the BM and PB are clinically crucial to achieve robust engraftment and faster hematopoietic recovery (36) .
To confirm that donor T cells are the major source of TNF in our model, we transplanted CD3 + T cell-depleted UCB and observed no significant difference between the etanercept and IgG control groups ( fig. S17 ). Note that etanercept treatment led to changes in the composition of donor T cell subsets present in the BM, with higher percentages of the central memory and T helper 17 (T H 17) subsets and lower percentages of the effector memory and T H 1 subsets. A higher percentage of plasmacytoid dendritic cells were also detected with etanercept treatment (fig. S18 ). To verify that the increase in HSPC engraftment in the BM is not the result of systemic GVHD mitigation by TNF blockade, we used a clinically effective GVHD-attenuating agent, tocilizumab (anti-IL-6 receptor antibody) (Fig. 7A) (22) . Although we observed similar GVHD scores between the etanercept and tocilizumab treatment groups ( fig. S19, F and K) , blocking IL-6 ( fig. S20 ) did not recapitulate the effect of blocking TNF to increase the percentage and number of phenotypically (Fig. 7B and fig. S19 , B and G) and functionally (Fig. 7C) defined progenitors engrafted in the BM and myeloid cells in the PB Heat map representation of human factor levels detected in the mouse serum after 17 days (from one experiment). Two-tailed Kruskal-Wallis and Mann-Whitney U tests with Bonferroni correction (P adj = 0.992) were used to determine the significance level. *P < 0.05; **P < 0.01; and ***P < 0.001. (fig. S21 ). In addition, treatment of etanercept showed no negative effects on short-term (17 days; fig. S22 ) and long-term (12 weeks; fig. S23 ) reconstitution when CD34 + cells were transplanted. Collectively, these data further support the findings that blocking TNF improves donor HSPC engraftment and reconstitution during the early phase of HSCT.
Next, to determine the effect of blocking TNF on the production of other donor-derived inflammatory factors, we measured serum concentrations of human factors. Consistent with previous reports (38) , etanercept treatment led to increased TNF levels, suggesting that etanercept binding to TNF prolongs its half-life in the serum. Other factor (IL-6 and IFN) levels were reduced with etanercept, suggesting that TNF might act as a key initiating catalyst for the inflammatory factor secretion cascade (Fig. 6D and fig. S24 ).
Last, we observed that at increasing UCB doses, administering etanercept resulted in greater numbers of engrafted phenotypically enriched ( fig. S25, B, E, and F) and functionally defined ( fig. S25, C and D) stem and progenitor cells. Moreover, transplantation of 3 × 10 6 unpurified UCB with etanercept resulted in higher engraftment levels of HSPCs compared to transplantation of CD34 + cells isolated from 3 × 10 6 UCB cells. These data demonstrate the numerical advantage of using unselected cells in HSCT when combined with etanercept treatment by preventing cell loss associated with cell selection.
DISCUSSION
Recent evidence has suggested that HSCs can be activated directly by inflammatory factors under stress conditions (39, 40) . Our study showed that inflammatory signals, generated by cotransplanted immune cells, can negatively affect donor HSPC function in a clinically relevant transplantation setting. We identified TNF as a central player in cascading the "cytokine storm" that directly impairs donor HSC survival, division, and engraftment. We further demonstrated that neutralizing TNF has two effects that are crucial in achieving successful post-HSCT outcomes (fig. S26 ). The first is an increase in the number and diversity of engrafted HSPCs in BM, which would ultimately promote stable long-term hematopoiesis. The second is an acceleration in the reconstitution of mature myeloid and megakaryocytic cells in PB, which facilitates timely hematopoietic recovery, thereby preventing neutropenia-and thrombocytopenia-associated complications (36) .
The role of TNF in regulating hematopoiesis has remained elusive. Several studies have shown stimulatory effects of TNF in progenitor cell proliferation and reconstitution (41, 42) , whereas other reports have implied that TNF exerts suppressive effects in HSPCs (29) (30) (31) (32) (43) (44) (45) (46) . There is evidence that the context-dependent effect of TNF in culture is linked to the presence of other growth factors (47, 48) . More recently, enhanced reconstitution of TNFR1 and TNFR2 double-knockout (Tnfrsf1-dKO) murine HSCs in serial transplantations has been demonstrated (49) . Here, we provide evidence that the human UCB-derived HSC population is sensitive to TNF signaling, directly prompting cell death and prolonging cell division time. This is consistent with recent observations that human HSCs have unique mechanisms to ultimately preserve HSC pool integrity in response to stress signals via selective apoptosis (50, 51) and regulation of cyclin-dependent kinase 6 (CDK6)-mediated G 0 exit (37) .
Aberrant production of TNF has been linked to many malignancies such as acute and chronic inflammatory diseases and BM failure syndromes. In allogeneic HSCT, TNF is elevated in the patient's serum, and higher TNF levels are associated with more severe GVHD and higher incidences of TRM (52) . Our findings uncover an additional, previously underappreciated, role for TNF in directly affecting donor HSC survival, division, and engraftment during the early phase of HSCT-a critical period for patient survival. The xenograft . Two-tailed Kruskal-Wallis and Mann-Whitney U tests with Bonferroni correction (P adj = 0.992) were used to determine the significance level. *P < 0.05; **P < 0.01; and ***P < 0.001.
model we used in this study is limited in mounting recipient immune responses, and the development of GVHD after 17 days prevented us from assessing long-term hematopoiesis upon etanercept treatment. Nonetheless, clinical data from an early phase 2 trial suggest that the use of etanercept as part of a prophylaxis treatment correlates with lower TRM and higher 1-year patient survival rates (53) . Further assessment of hematopoietic reconstitution in patients receiving etanercept as a preemptive therapy is necessary to evaluate the clinical relevance of the TNF blockade approach. In addition, our systemwide mass cytometry analysis identifies the activated subsets of donor-derived memory T cells as the major source of TNF, reminiscent of the phenotypic changes of T cells seen in the PB of patients within 28 days of UCB transplantation (54) . Identification of antigens that stimulate donor T cell reactivity will aid in developing strategies to "design" a graft that enables the control of the signaling environment during the early phase of HSCT, by optimizing the composition of beneficial (normal or genetically engineered) T cell subsets (55) and specifically suppressing the undesired T cell phenotypes after transplantation.
In conclusion, our study establishes the role of TNF in hematopoietic reconstitution in a clinically relevant HSCT model. Blocking TNF signaling is a promising therapeutic strategy to protect donor HSCs and progenitors from the host's detrimental inflammatory signals after transplant. The use of clinically available TNF-neutralizing biologics may provide several advantages in transplantation of not only UCB but also other cell sources to (i) enhance stem and progenitor cell engraftment, (ii) accelerate peripheral hematopoietic recovery, and (iii) reduce substantial cell loss and costs associated with cell selection. These advantages will broaden the use of normal or genetically manipulated blood stem cells for the treatment of hematologic and nonhematologic diseases.
MATERIALS AND METHODS
Study design
Our objective was to characterize the effect of donor immune cell-derived inflammatory signals on transplanted HSPC fate in a clinically relevant transplantation setting. For in vivo transplant studies, no power analysis was performed to predetermine the sample size, animals were randomly allocated to treatment groups and randomly housed to minimize environmental factors that might confound the experimental outcomes, and endpoint analyses were performed in a blinded fashion. Sample size and number of replicates for each experiment are specified in figure legends. For in vitro cell culture experiments, cell samples pooled from at least two donors were used in individual experiments, and at least two independent experiments were performed.
Statistical analysis
Unpaired two-tailed Kruskal-Wallis and Mann-Whitney U tests were performed to test the statistical significance of the data due to non-normality assessed by the Shapiro-Wilk normality test. Bonferroni correction was applied for multiple comparisons as appropriate. We used R packages (version 3.0.2) for all statistical analyses with the  value set at 0.05 (unless otherwise stated).
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